a NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust , Oxford , United Kingdom.
b Oxford Eye Hospital, University of Oxford NHS Trust, John Radcliffe Hospital , Oxford , United Kingdom.
Ocul Immunol Inflamm. 2019;27(5):693-698. doi: 10.1080/09273948.2017.1370651. Epub 2017 Oct 17.
: We report two new CAPN5 mutations associated with a phenotype of Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy. : We performed next generation sequencing in two patients with ADNIV phenotype; the variants identified were explored further. : Patient 1 was heterozygous for CAPN5 c.799G>A, p.(Gly267Ser). Patient 2 was heterozygous for CAPN5 c.1126G>A, p.(Gly376Ser). Both amino acids are highly conserved across species. Patient 1 had a severe phenotype and his mutation lies within the protein's catalytic domain. Patient 2 had a mild phenotype and her mutation is the first ADNIV-causing mutation to be described in the regulatory domain of Calpain-5. : Our findings potentially add two new ADNIV-causing CAPN5 mutations to the three previously described. We recommend CAPN5 genetic testing in all patients with a possible ADNIV phenotype, to develop our understanding of Calpain-5; a protein which could potentially provide therapeutically accessible targets for the treatment of many leading causes of blindness.
我们报告了两个与常染色体显性新生血管性炎症性玻璃体视网膜病变表型相关的 CAPN5 新突变。我们对两个具有 ADNIV 表型的患者进行了下一代测序;进一步探讨了鉴定出的变体。患者 1 为 CAPN5 c.799G>A,p.(Gly267Ser)杂合子。患者 2 为 CAPN5 c.1126G>A,p.(Gly376Ser)杂合子。这两个氨基酸在不同物种中高度保守。患者 1 表现出严重的表型,其突变位于蛋白的催化结构域内。患者 2 的表型较轻,她的突变是第一个在 Calpain-5 调节结构域中描述的导致 ADNIV 的突变。我们的发现可能为先前描述的三个突变增加了两个新的导致 ADNIV 的 CAPN5 突变。我们建议对所有可能具有 ADNIV 表型的患者进行 CAPN5 基因检测,以加深对 Calpain-5 的理解;这种蛋白可能为治疗许多主要致盲原因提供可治疗的靶向治疗。